Archive summary Clinical & research

Axsome Therapeutics Wins FDA Nod for Auvelity in Alzheimer’s Agitation, Launch Set for June

Axsome Therapeutics (NASDAQ:AXSM) announced that the U.S. Food and Drug Administration has approved Auvelity for the treatment of agitation associated with dementia due to Alzheimer’s disease, expanding the product’s indications beyond major depressive disorder. The approval and the company’s commer

Summary of reporting by thelincolnianonline May 3, 2026 1 min read Markdown